
|Videos|January 22, 2015
Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer
Author(s)Edith A. Perez, MD,
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.
Advertisement
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.
The BEACON trial (BrEAst Cancer Outcomes with NKTR-102) is an important study for refractory HER2-negative breast cancer, says Perez. It looks at the new compound etirinotecan pegol (NKTR-102), a long-acting topoisomerase-1 inhibitor designed for prolonged tumor cell exposure, in comparison to physicians’ choice of treatment.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































